# 3D Systems Corp: Form 10-Q for the period ended Sep 30, 2022

- Company: [3D Systems Corp](/companies/ddd.md) (CIK 910638)
- Form: 10-Q
- Filed: 2022-11-09
- Accepted by EDGAR: Nov 9, 2022, 17:20 ET
- Period: 2022-09-30
- Accession: 0000910638-22-000046
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/910638/000091063822000046/ddd-20220930.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/910638/000091063822000046/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2022-09-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2022-07-01 to 2022-09-30 | $132.3m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 9 months, 2022-01-01 to 2022-09-30 | $405.3m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months, 2022-07-01 to 2022-09-30 | $79.6m | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 9 months, 2022-01-01 to 2022-09-30 | $245.7m | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 3 months, 2022-07-01 to 2022-09-30 | $52.7m | us-gaap:GrossProfit |
| Gross profit | 9 months, 2022-01-01 to 2022-09-30 | $159.6m | us-gaap:GrossProfit |
| Research and development | 3 months, 2022-07-01 to 2022-09-30 | $20.8m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months, 2022-01-01 to 2022-09-30 | $63.2m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months, 2022-07-01 to 2022-09-30 | $65.6m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 9 months, 2022-01-01 to 2022-09-30 | $185.4m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months, 2022-07-01 to 2022-09-30 | −$33.7m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months, 2022-01-01 to 2022-09-30 | −$89.0m | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months, 2022-07-01 to 2022-09-30 | $338.0k | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months, 2022-01-01 to 2022-09-30 | $2.9m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2022-07-01 to 2022-09-30 | −$37.4m | us-gaap:NetIncomeLoss |
| Net income | 9 months, 2022-01-01 to 2022-09-30 | −$97.2m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2022-07-01 to 2022-09-30 | −$0.30 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months, 2022-01-01 to 2022-09-30 | −$0.77 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2022-07-01 to 2022-09-30 | −$0.30 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months, 2022-01-01 to 2022-09-30 | −$0.77 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2022-07-01 to 2022-09-30 | 127,991,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months, 2022-01-01 to 2022-09-30 | 127,478,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months, 2022-01-01 to 2022-09-30 | −$52.4m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months, 2022-01-01 to 2022-09-30 | $17.1m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | at 2022-09-30 | $341.3m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2022-09-30 | $865.3m | us-gaap:AssetsCurrent |
| Total assets | at 2022-09-30 | $1.43bn | us-gaap:Assets |
| Current liabilities | at 2022-09-30 | $152.4m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2022-09-30 | $695.5m | us-gaap:Liabilities |
| Long-term debt | at 2022-09-30 | $448.9m | us-gaap:LongTermDebtNoncurrent |
| Shareholders' equity | at 2022-09-30 | $734.3m | us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest |

## Management's discussion and analysis

As filed, 61,915 characters.

The following discussion and analysis should be read together with the unaudited condensed consolidated financial statements and the notes thereto included in Item 1, (the “Financial Statements”). Also, we are subject to a number of risks and uncertainties that may affect our future performance that are discussed in greater detail under the heading "Forward Looking Statements" below and in Part I, Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2021 ("2021 Form 10-K") and below in Part II, Item 1A in this Form 10-Q for the quarter ended June 30, 2022 under the heading "Risk Factors".

### Business Overview

3D Systems Corporation (“3D Systems” or the “Company” or “we,” "our" or “us”) markets our products and services through subsidiaries in North America and South America (collectively referred to as “Americas”), Europe and the Middle East (collectively referred to as “EMEA”) and the Asia Pacific and Oceania region (collectively referred to as “APAC”). We provide comprehensive 3D printing and digital manufacturing solutions, including 3D printers for plastics and metals, materials, software, and digital design tools. Our solutions support advanced applications in two key industry verticals: Healthcare (which includes dental, medical devices, personalized health services and regenerative medicine) and Industrial (which includes aerospace, defense, transportation and general manufacturing). We have over 35 years of experience and expertise which have proven vital to our development of an ecosystem and end-to-end digital workflow solutions which enable customers to optimize product designs, transform workflows, bring innovative products to market and drive new business models.

The Company has two reportable segments, Healthcare and Industrial.

#### Overview and Strategy

In May 2020, our Chief Executive Officer and President, Dr. Jeffrey Graves, was hired. Dr. Graves undertook an initial assessment of the Company and developed the purpose statement to be the leader in enabling additive manufacturing solutions for applications in growing markets that demand high reliability products. He announced a four-phased plan to enable this vision: reorganize into two key industry verticals (Healthcare and Industrial), restructure to gain efficiencies, divest non-core assets, and invest for future growth.

As part of our strategic plan, we have organized into two key verticals. This structure allows us to align our solution-oriented approach with deep industry and customer knowledge. Our two key verticals span a range of industries. Healthcare includes dental, medical devices, personalized health services and regenerative medicine. Our Industrial vertical includes aerospace, defense, transportation and general manufacturing. We architect solutions specific to customers’ needs through a combination of materials, hardware platforms, software, professional services and advanced manufacturing – creating a path to integrating additive manufacturing into traditional production environments. As a result, manufacturers achieve design freedom, increase agility, scale production and improve overall total cost of operation. Our technologies and process knowledge enable hundreds of thousands of production parts to be made through additive manufacturing each day.

In conjunction with our four-phased plan, we completed our initial restructuring efforts in the second quarter of 2021. Cost reduction efforts included reducing the number of facilities and examining every aspect of our manufacturing and operating costs. However, given the current macroeconomic challenges, we will continue to look for ways to manage costs. In the second quarter of 2022, we notified one of our printer assembly outsourcing partners of our intent to terminate the manufacturing services arrangement and in-source our printer assembly and production process, as we believe this is an opportunity to improve customer delivery and reduce costs. We completed the in-sourcing in July of 2022.

#### Divestitures (see Note 2 of the Financial Statements for further details)

In the second quarter of 2022, we notified one of our contract manufacturers of our intent to terminate the manufacturing services arrangement and in-source the assembly and production process. The exit agreement was finalized in July 2022 and includes a $1.7 million exit fee accrued in the second quarter of 2022 and paid in third quarter of 2022, as well as the commitment to purchase $23.9 million of inventory and $0.4 million of fixed assets from the assembly manufacturer. Part of the inventory purchased was prepaid during previous quarters for $8.9 million which resulted in a net payment of $17.1 million in July 2022.

In conjunction with our four-phased plan, we divested parts of our business that did not align with our strategic focus on additive manufacturing. The divestitures were completed in 2021, with net proceeds totaling $421.5 million. In January 2021, we sold Cimatron Ltd., which operated our Cimatron integrated CAD/CAM software for the tooling business and its GibbsCAM CNC programming software business. In August 2021, we sold our Simbionix line of surgical simulators. In September 2021, we sold our On Demand Manufacturing ("ODM"). These divestitures represent the completion of our planned divestitures of non-core assets as part of the strategic plan noted above.

#### Acquisitions (See Note 2 of the Financial Statements for Further Details)

The last phase of the plan was to invest in growth. Once the restructuring phase and the divestitures of non-core assets were complete, the company made several acquisitions and investments.

On April 1, 2022, we completed the acquisition of 93.75% of Kumovis GmbH ("Kumovis") for an all-cash purchase price of $37.7 million. The payment of $3.6 million is deferred for up to fifteen months from the closing date. Kumovis, which is part of the Healthcare segment, utilizes polyether ether keton or “PEEK” materials, which have properties that lend it to many medical applications, including many implant applications, that fit into our personalized healthcare operations. The impact of the acquisition is not expected to have a near-term material impact to the Company's financial position, statement of operations or cash flows.

On April 1, 2022, we completed the 100% acquisition of Titan Additive LLC ("Titan") for an all-cash purchase price of $39.0 million. Titan, which is part of the Industrial segment, is a pellet-based extrusion platform that addresses customer applications requiring large build volumes, superior performance, and improved productivity at significantly lower cost. We believe the acquisition of Titan will open up new markets in the Industrial segment. The impact of the acquisition is not expected to have a near-term material impact to the Company's financial position, statement of operations or cash flows.

In March 2022, the Saudi Arabian Industrial Investments Company ("Dussur") and 3D Systems signed an agreement to form a joint venture intended to expand the use of additive manufacturing within the Kingdom of Saudi Arabia and surrounding geographies, including the Middle East and North Africa. The joint venture is to enable the development of Saudi Arabia's domestic additive manufacturing production capabilities, consistent with the Kingdom’s ‘Vision 2030,’ which is focused on diversification of the economy and long-term sustainability. Once the joint venture is formed, 3D Systems will own approximately 49% and is committed to an initial investment of about $6.5 million. Additional future investments are contingent upon the achievement of certain milestones by the joint venture. The expected impact on the Company’s financial position, results of operations and cash flows will not be material other than the cash outflow(s) related to the initial and contingent investments.

In March 2022, we made a $10.0 million investment for an approximate 26.6% ownership interest in Enhatch Inc. ("Enhatch"), the developer of the Intelligent Surgery Ecosystem. We simultaneously entered into a collaboration and supply agreement with Enhatch. We also obtained warrants to purchase additional shares of Enhatch and the right to purchase, in the future, the remaining shares of Enhatch that 3D Systems does not own if certain revenue targets are achieved. Enhatch's Intelligent Surgery Ecosystem provides technologies which streamline and scale the design and delivery of patient-specific medical devices by automating the process. Incorporating these capabilities into 3D Systems’ workflow for patient-specific solutions, which includes advanced software, expert treatment planning services, custom implants, instrumentation design, and industry-leading production processes, will help more efficiently meet the growing demand for personalized medical devices. The expected impacts on the Company’s financial position, results of operations and cash flows are not material other than potential future cash used to exercise the warrants or call option.

During the three months ended September 30, 2022, the Company recorded an impairment charge of $2.8 million related to the carrying value of its investment in Enhatch. This impairment charge was the result of lower than projected revenues recognized by Enhatch during the quarter, as well as a reduction to near-term forecasted revenues due to a delay in receiving certain regulatory approvals. In addition, the carrying value of the Enhatch warrants, which are required to be recorded at their fair value as of the end of each quarter, was reduced from $0.3 million to $0.2 million. The Company has recorded the impairment charge related to its Enhatch investment, as well as the change in the value of the Enhatch warrants, within Interest and other income (expense), net on the statements of operations for the three and nine months ended September 30, 2022.

On December 1, 2021, we acquired Volumetric Biotechnologies, Inc. (“Volumetric”), for $40.2 million. Additional payments of up to $355.0 million are possible upon (1) the attainment of seven non-financial milestones, each of which requires achievement prior to either December 31, 2030 and 2035, and (2) the continued employment of certain key individuals from Volumetric. Volumetric’s mission is to develop the ability to manufacture human organs using bioprinting methods and the underlying technologies required to create these highly complex biological structures. With this acquisition, 3D Systems expanded our capabilities and capacity in 3D printing related to bio-printing and regenerative medicine. Combining 3D Systems' regenerative medicine group with Volumetric’s highly complementary skill sets of biological expertise and cellular engineering is expected to accelerate our core regenerative medicine strategies which include the bio-printing of human organs, additional non-organ applications and bio-printing technologies for research labs. The acquisition’s near-term impact on the Company's financial position, results of operations and cash flows are expected to be dilutive. Volumetric's operating results are reported in the Healthcare segment.

On November 1, 2021, we acquired Oqton, Inc. (“Oqton”), for $187.8 million. Oqton is a software company that creates an intelligent, cloud-based Manufacturing Operating System (MOS) platform tailored for flexible production environments that increasingly utilize a range of advanced manufacturing and automation technologies, including additive manufacturing solutions, in their production workflows. The cloud-based solution leverages the Industrial Internet of Things, artificial intelligence, and machine learning technologies to deliver a solution for customers to automate their digital manufacturing workflows, scale their operations and enhance their competitive position. The Oqton acquisition will allow the Company to expand its existing additive manufacturing software suite to the entire additive industry. Oqton's operating results are reported in the Industrial segment and the acquisition’s impact on the Company’s financial position, results of operations and cash flows have been dilutive.

In May 2021, we purchased Allevi, Inc. to expand regenerative medicine initiatives into medical and pharmaceutical research and development laboratories. Additionally, in June 2021, we closed the acquisition of a German software firm, Additive Works GmbH (“Additive”). Additive expands the simulation capabilities for rapid optimization of industrial-scale 3D printing processes. The purchase price for both acquisitions, individually and combined, and the impacts to the Company’s financial position, results of operations and cash flows are not material.

### COVID-19 Pandemic and Current Economic Environment

The COVID-19 pandemic continues to impact the global economy, disrupt global supply chains, and create significant volatility in the financial markets. These factors have resulted in inflationary and cost pressures that have significantly increased, and continue to adversely impact, our production and distribution costs, including costs of spare parts and materials, packaging materials, and freight. We continue to experience pressure on our supply chain due to strained transportation capacity, lack of sufficient labor availability, and manufacturing backlogs. In addition, the Russia conflict with Ukraine led to our exit from the Russian market early this year, and the conflict continues to exacerbate inflationary cost pressures and supply chain constraints which are negatively impacting the global economy and our business.

Due to the COVID-19 pandemic, our affiliates, employees, suppliers, customers, and others have been restricted or prevented from conducting normal business activities, including shutdowns, travel restrictions and other actions that may be requested or mandated by governmental authorities. While these restrictions have eased since 2021, if the COVID-19 pandemic resurges, governmental authorities may reimpose additional health and safety requirements which could again restrict or prevent normal business activities. Our offices are currently open and business travel has resumed, with safety measures in place and in accordance with local guidance.

We are managing our operations, continuing to monitor the ongoing impacts of COVID-19, and reviewing guidance from international and domestic authorities. We remain committed to protecting our employees, delivering for our customers, and supporting our communities.

The COVID-19 pandemic and other factors impacting the current economic environment, such as inflation, weak economic conditions, including the possibility of a recession, and equity market volatility continued to impact our reported results for the year ended December 31, 2021, as well as the three and nine months ended September 30, 2022. We are unable to predict the longer-term impact that these factors may have on our business, results of operations, financial position or cash flows. The extent to which our operations may be impacted will depend largely on future developments, which are highly uncertain and cannot be accurately predicted, including the severity or resurgence of a COVID-19 outbreak, actions by government authorities to contain an outbreak or treat its impact, actions by government authorities to address inflationary and cost pressures, and the severity, length, and potential expansion of the conflict in Ukraine. The impacts of these uncertain global health, economic and geopolitical conditions could result in reduced customer demand due to delays in purchasing decisions or the reduction in use of our services, further supply chain disruptions, including the shortages of critical components, and continued disruptions to, and volatility in, the financial markets. Events surrounding the global economy, geopolitics, and the COVID-19 pandemic continue to evolve. Although we believe that we will ultimately emerge from these events well positioned for long-term growth, uncertainties remain and, as such, we cannot reasonably estimate the duration or extent of these adverse factors on our business, results of operations, financial position, or cash flows.

#### Background

We earn revenue from the sale of products and services through our Healthcare and Industrial segments. The product categories include 3D printers and corresponding materials, healthcare simulators (which was divested in third quarter of 2021), digitizers, software licenses, 3D scanners and haptic devices. The majority of materials used in our 3D printers are proprietary. The services category includes maintenance contracts and services on 3D printers and simulators, software maintenance, software as a service subscriptions, on-demand solutions (which was divested in the third quarter of 2021) and healthcare services.

Given the relatively high price of certain 3D printers and a corresponding lengthy selling cycle, as well as relatively low unit volume of the higher-priced printers in any particular period, a shift in the timing and concentration of orders and shipments from one period to another can materially affect reported revenue in any given period.

In addition to changes in sales volumes, there are three other primary drivers of changes in revenue from one period to another: (1) divestitures, (2) the combined effect of changes in product mix and average selling prices and (3) the impact of fluctuations in foreign currencies. As used in this Management’s Discussion and Analysis, the price and mix effects relate to changes in revenue that are not able to be specifically related to changes in unit volume, divestitures or foreign exchange.

### Summary of Financial Results for the Three and Nine Months Ended September 30, 2022

*(in thousands)*

| Revenue: | Three Months Ended September 30, 2022 | 2021 | Nine Months Ended September 30, 2022 | 2021 |
| --- | ---: | ---: | ---: | ---: |
| Products | $96,337 | $108,884 | $300,662 | $311,170 |
| Services | 35,916 | 47,212 | 104,637 | 153,599 |
| Total revenue | 132,253 | 156,096 | 405,299 | 464,769 |
| Cost of sales: |  |  |  |  |
| Products | 58,042 | 64,252 | 181,845 | 180,251 |
| Services | 21,541 | 27,529 | 63,851 | 86,958 |
| Total cost of sales | 79,583 | 91,781 | 245,696 | 267,209 |
| Gross profit | 52,670 | 64,315 | 159,603 | 197,560 |
| Operating expenses: |  |  |  |  |
| Selling, general and administrative | 65,579 | 65,737 | 185,398 | 176,800 |
| Research and development | 20,796 | 15,786 | 63,180 | 49,987 |
| Total operating expenses | 86,375 | 81,523 | 248,578 | 226,787 |
| Loss from operations | $(33,705) | $(17,208) | $(88,975) | $(29,227) |

38

#### Three months ended September 30, 2022 compared to the three months ended September 30, 2021

Total consolidated revenue for the three months ended September 30, 2022 decreased $23.8 million, or 15.3%, compared to the same period last year, primarily driven by divestitures of non-core businesses and the negative impacts of foreign exchange. Revenue from divested businesses in the third quarter of 2021 was $19.4 million and foreign exchange negatively impacted revenue in the third quarter of 2022 by $8.2 million. The $12.5 million decrease in products revenue is primarily due to divestitures of $5.4 million, the negative impacts of foreign exchange of $6.2 million, and lower sales volumes in the dental market, partially offset by higher volumes and favorable sales price/mix in other markets. The $11.3 million decrease in services revenue is primarily due to divestitures of $14.0 million and the negative impact of foreign exchange of $2.0 million, partially offset by higher sales volumes of $4.7 million.

Gross profit for the three months ended September 30, 2022 decreased $11.6 million, or 18.1%, to $52.7 million, compared to $64.3 million for the three months ended September 30, 2021. The gross profit margin for the three months ended September 30, 2022 and 2021 was 39.8% and 41.2%, respectively. The decrease in products and services gross profit and gross profit margin is primarily a result of divestitures of $9.4 million, cost inflation, supply chain pressures, and higher freight costs.

Operating expenses for the three months ended September 30, 2022 increased $4.9 million, or 6.0%, to $86.4 million, compared to $81.5 million for the three months ended September 30, 2021. Selling, general and administrative (“SG&A”) expenses for the three months ended September 30, 2022 decreased $0.2 million, or 0.2%, to $65.6 million, compared to $65.7 million for the same period last year due to lower incentive compensation expense of $13.4 million and the decrease in expenses due to divestitures of $3.3 million, substantially offset by a $9.0 million increase in expenses for estimated costs from legal contingencies and other settlements and a $4.4 million increase in expenses due to acquisitions. Research and development (“R&D”) expenses for the three months ended September 30, 2022 increased $5.0 million, or 31.7%, to $20.8 million, due to expenses from acquisitions of $4.6 million and continued investments in growth initiatives, partly offset by the absence of expenses from divested businesses of $1.4 million.

Our operating loss for the three months ended September 30, 2022 was $33.7 million, compared to a $17.2 million operating loss for the three months ended September 30, 2021, due to lower gross profit and higher R&D expenses as discussed above.

#### Nine months ended September 30, 2022 compared to the nine months ended September 30, 2021

Total consolidated revenue for the nine months ended September 30, 2022 decreased $59.5 million, or 12.8%, compared to the same period last year, primarily driven by divestitures of non-core businesses and the negative impacts of foreign exchange, partly offset by higher sales volumes. Revenue from divested businesses for the nine months ended September 30, 2021 was $71.7 million, foreign exchange negatively impacted revenue in the nine months ended September 30, 2022 by $17.5 million, and higher sales volumes resulted in a $29.6 million increase in revenue. The $10.5 million decrease in products revenue is primarily due to divestitures of $23.0 million, the negative impacts of foreign exchange of $12.9 million, and lower sales volumes in the dental market, partly offset by higher volumes and favorable sales price/mix in other markets. The $49.0 million decrease in services revenue is due to divestitures of $48.7 million and the negative impact of foreign exchange of $4.6 million partially offset by higher sales volumes of $4.3 million.

Gross profit for the nine months ended September 30, 2022 decreased $38.0 million, or 19.2%, to $159.6 million, compared to $197.6 million for the nine months ended September 30, 2021. Gross profit margin for the nine months ended September 30, 2022 and September 30, 2021 was 39.4% and 42.5%, respectively. The decrease in products and services gross profit and gross profit margin is primarily a result of divestitures of $33.5 million, cost inflation, supply chain pressures, and higher freight costs.

Operating expenses for the nine months ended September 30, 2022 increased $21.8 million, or 9.6%, to $248.6 million, compared to $226.8 million for the nine months ended September 30, 2021. SG&A expenses for the nine months ended September 30, 2022 increased $8.6 million, or 4.9%, to $185.4 million, compared to $176.8 million for the same period last year due to an increase in expenses for estimated costs from legal contingencies and other settlements of $19.2 million, expenses from acquired companies of $11.1 million, Volumetric contingent consideration of $12.0 million, and an increase in merger and acquisition expenses, partly offset by lower incentive compensation expense of $28.6 million and the absence of expenses from divested businesses of $12.0 million. R&D expenses for the nine months ended September 30, 2022 increased $13.2 million, or 26.4%, to $63.2 million, due to expenses from acquisitions of $14.0 million and continued investments in growth initiatives, partly offset by the absence of expenses from divested businesses of $5.3 million.

Our operating loss for the nine months ended September 30, 2022 was $89.0 million, compared to a $29.2 million operating loss for the nine months ended September 30, 2021, due to lower gross profit and higher SG&A and R&D expenses as discussed above.

### Three months ended September 30, 2022 compared to the three months ended September 30, 2021

#### Segments income statement

The following table sets forth our operating results by segment:

*(in thousands)*

|  | Three Months Ended September 30, 2022 Healthcare | Industrial | Consolidated | 2021 Healthcare | Industrial | Consolidated |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $64,203 | $68,050 | $132,253 | $76,365 | $79,731 | $156,096 |
| Cost of sales | 39,547 | 40,036 | 79,583 | 44,735 | 47,046 | 91,781 |
| Gross profit | 24,656 | 28,014 | 52,670 | 31,630 | 32,685 | 64,315 |
| Less: |  |  |  |  |  |  |
| Segment operating expenses | 18,151 | 21,442 | 39,593 | 22,576 | 19,487 | 42,063 |
| Segment operating income | $6,505 | $6,572 | 13,077 | $9,054 | $13,198 | 22,252 |
| General corporate expense, net (a) |  |  | 46,782 |  |  | 39,460 |
| Operating (loss) |  |  | $(33,705) |  |  | $(17,208) |

(a) - General corporate expense, net includes expenses not specifically attributable to our segments for functions such as human resources, finance, legal and information technology, including salaries, benefits, and other related costs, company-wide incentive compensation and stock-based compensation.

For the three months ended September 30, 2022, Healthcare revenue decreased $12.2 million, or 15.9%, compared to the same period last year primarily due to divestitures, the negative impacts of foreign exchange, and lower sales volumes in the dental market, partly offset by higher volumes and favorable sales price/mix in other markets. For the three months ended September 30, 2022 and 2021, products revenue from Healthcare contributed $43.0 million and $55.5 million, respectively. The decrease in products revenue in Healthcare is primarily due to divestitures, lower sales volumes in the dental market, and the negative impacts of foreign exchange, partially offset by higher sales volumes in other markets. For the three months ended September 30, 2022 and 2021, services revenue from Healthcare contributed $21.3 million and $20.9 million, respectively.

For the three months ended September 30, 2022, Industrial revenue decreased $11.7 million, or 14.7%, compared to the same period last year primarily due to divestitures and the negative impacts of foreign exchange, partially offset by higher sales volumes. For the three months ended September 30, 2022 and 2021, products revenue from Industrial contributed $53.4 million and $53.4 million, respectively. Products revenue in Industrial was flat, with higher sales volumes being offset by the negative impacts of foreign exchange. For the three months ended September 30, 2022 and 2021, services revenue from Industrial contributed $14.7 million and $26.4 million, respectively. The decrease in services revenue in the Industrial segment is due to divestitures and the negative impacts of foreign exchange, partially offset by higher sales volumes.

For the three months ended September 30, 2022, Healthcare gross profit decreased $7.0 million compared to the same period last year. Further, the gross profit margin decreased to 38.4% for the three months ended September 30, 2022 compared to 41.4% in the same period last year. The year over year decrease in Healthcare gross profit margin is primarily due to divestitures and lower sales volumes in the dental market, partially offset by higher sales volumes in other markets.

For the three months ended September 30, 2022, Industrial gross profit decreased $4.7 million, compared to the same period last year primarily due to divestitures. The gross profit margin of 41.2% for the three months ended September 30, 2022 increased from 41.0% in the same period last year. The year over year increase in gross profit margin was primarily due to favorable product mix changes.

For the three months ended September 30, 2022, Healthcare operating expenses decreased $4.4 million, or 19.6%, compared to the same period last year. This decrease primarily relates to a $6.2 million decrease in SG&A costs related to divestitures, partially offset by a $1.9 million increase in Healthcare’s allocated portion of R&D costs that are shared between the Company’s two operating segments.

For the three months ended September 30, 2022, Industrial operating expenses increased $2.0 million, or 10.0%, compared to the same period last year. This increase primarily relates to a $3.4 million increase in Industrial’s allocated portion of R&D costs that are shared between the Company’s two operating segments, offset by a $1.5 million decrease in SG&A costs attributable to the segment.

#### Revenue

The following table sets forth the change in revenue for the three months ended September 30, 2022 and 2021.

*(Dollars in thousands)*

|  | Products |  | Services |  | Total |  |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue — third quarter 2021 | $108,884 |  | $47,212 |  | $156,096 |  |
| Change in revenue: |  |  |  |  |  |  |
| Volume | (2,955) | (2.7)% | 4,749 | 10.1% | 1,794 | 1.1% |
| Divestitures | (5,354) | (4.9)% | (14,049) | (29.8)% | (19,403) | (12.4)% |
| Price/Mix | 1,942 | 1.8% | — | —% | 1,942 | 1.2% |
| Foreign currency translation | (6,180) | (5.7)% | (1,996) | (4.2)% | (8,176) | (5.2)% |
| Net change | (12,547) | (11.5)% | (11,296) | (23.9)% | (23,843) | (15.3)% |
| Revenue — third quarter 2022 | $96,337 |  | $35,916 |  | $132,253 |  |

Total consolidated revenue for the three months ended September 30, 2022 decreased $23.8 million, or 15.3%, compared to the same period last year, driven by divestitures of non-core businesses and the negative impact of foreign exchange. Revenue from divested businesses in the third quarter of 2021 was $19.4 million, and foreign exchange negatively impacted revenue in the third quarter of 2022 by $8.2 million. Challenging macroeconomic conditions adversely impacted products sales volumes in the dental market, partially offset by higher sales volumes in other markets.

#### Gross profit and gross profit margins

The following table sets forth gross profit and gross profit margins for the three months ended September 30, 2022 and 2021.

*(Dollars in thousands)*

|  | Three Months Ended September 30, 2022 Gross Profit | Gross Profit Margin | 2021 Gross Profit | Gross Profit Margin | Change in Gross Profit $% |  | Change in Gross Profit Margin Percentage Points% |  |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Products | $38,295 | 39.8% | $44,632 | 41.0% | $(6,337) | (14.2)% | (1.2) | (2.9)% |
| Services | 14,375 | 40.0% | 19,683 | 41.7% | (5,308) | (27.0)% | (1.7) | (4.1)% |
| Total | $52,670 | 39.8% | $64,315 | 41.2% | $(11,645) | (18.1)% | (1.4) | (3.4)% |

Gross profit for the three months ended September 30, 2022, decreased $11.6 million, or 18.1%, to $52.7 million, compared to $64.3 million for the three months ended September 30, 2021. The gross profit margin for the three months ended September 30, 2022 and 2021 were 39.8% and 41.2%, respectively. The decrease in products and services gross profit and gross profit margin is primarily a result of divestitures of $9.4 million, cost inflation, supply chain pressures, and higher freight costs.

#### Operating expenses

The following table sets forth the components of consolidated operating expenses for the three months ended September 30, 2022 and 2021.

*(Dollars in thousands)*

|  | Three Months Ended September 30, 2022 Amount | % Revenue | 2021 Amount | % Revenue | Change $% |  |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Selling, general and administrative expenses | $65,579 | 49.6% | $65,737 | 42.1% | $(158) | (0.2)% |
| Research and development expenses | 20,796 | 15.7% | 15,786 | 10.1% | 5,010 | 31.7% |
| Total operating expenses | $86,375 | 65.3% | $81,523 | 52.2% | $4,852 | 6.0% |

For the three months ended September 30, 2022, as compared to the same period last year, SG&A expenses are flat, primarily due to lower incentive compensation expense of $13.4 million and the decrease in expenses due to divestitures of $3.3 million, which were substantially offset by a $9.0 million increase in expenses for estimated costs from legal contingencies and other settlements and a $4.4 million increase in expenses due to acquisitions.

For the three months ended September 30, 2022, as compared to the same period last year, R&D expenses increased $5.0 million due to expenses from acquisitions of $4.6 million and continued investments in growth initiatives, partly offset by the absence of expenses from divested businesses of $1.4 million.

### Nine months ended September 30, 2022 compared to the nine months ended September 30, 2021

#### Segments income statement

The following table sets forth our operating results by segment:

*(in thousands)*

|  | Nine Months Ended September 30, 2022 Healthcare | Industrial | Consolidated | 2021 Healthcare | Industrial | Consolidated |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $200,295 | $205,004 | $405,299 | $231,712 | $233,057 | $464,769 |
| Cost of sales | 124,309 | 121,387 | 245,696 | 127,600 | 139,609 | 267,209 |
| Gross profit | 75,986 | 83,617 | 159,603 | 104,112 | 93,448 | 197,560 |
| Less: |  |  |  |  |  |  |
| Segment operating expenses | 52,908 | 68,296 | 121,204 | 53,012 | 57,770 | 110,782 |
| Segment operating income | $23,078 | $15,321 | 38,399 | $51,100 | $35,678 | 86,778 |
| General corporate expense, net (a) |  |  | 127,374 |  |  | 116,005 |
| Operating (loss) |  |  | $(88,975) |  |  | $(29,227) |

(a) - General corporate expense, net includes expenses not specifically attributable to our segments for functions such as human resources, finance, legal and information technology, including salaries, benefits, and other related costs, company-wide incentive compensation and stock-based compensation.

For the nine months ended September 30, 2022, Healthcare revenue decreased $31.4 million, or 13.6%, as compared to the same period last year primarily due to divestitures, the negative impacts of foreign exchange, and lower sales volumes in the dental market, partly offset by higher volumes and favorable sales price/mix in other markets. For the nine months ended September 30, 2022 and 2021, products revenue from Healthcare contributed $141.0 million and $162.9 million, respectively. The decreased products revenue in Healthcare is primarily due to divestitures of $26.6 million and lower sales volumes in the dental market, partially offset by higher volumes and favorable sales price/mix in other markets. For the nine months ended September 30, 2022 and 2021, services revenue from Healthcare contributed $59.3 million and $68.8 million, respectively. The lower services revenue in Healthcare is primarily due to divestitures.

For the nine months ended September 30, 2022 , Industrial revenue decreased $28.1 million, or 12.0%, as compared to the same period last year primarily due to divestitures and the negative impacts of foreign exchange partially offset by higher sales volumes. For the nine months ended September 30, 2022 and 2021, products revenue from Industrial contributed $159.7 million and $148.2 million, respectively. The increase in Industrial products revenue was primarily due to higher sales volumes, partially offset by the negative impact of foreign exchange. For the nine months ended September 30, 2022 and 2021, services revenue from Industrial contributed $45.3 million and $84.8 million, respectively. The lower services revenue in Industrial is primarily due to divestitures and the negative impacts of foreign exchange partially offset by higher sales volumes.

For the nine months ended September 30, 2022 Healthcare gross profit decreased $28.1 million compared to the same period last year. Further, the gross profit margin decreased to 37.9% for the nine months ended September 30, 2022, compared to 44.9% in the same period last year. The year over year decrease in Healthcare gross profit and gross profit margin is primarily due to product mix changes, divestitures of $15.1 million and inflationary pressures, particularly freight and component costs.

For the nine months ended September 30, 2022 Industrial gross profit decreased $9.8 million compared to the same period last year. Further, the gross profit margin increased to 40.8% for the nine months ended September 30, 2022 compared to 40.1% in the same period last year. The year over year decrease in gross profit is primarily due to divestitures of $18.4 million, partly offset by an increase in sales volumes.

For the nine months ended September 30, 2022, Healthcare operating expenses were flat compared to the same period last year.

For the nine months ended September 30, 2022, Industrial operating expenses increased $10.5 million, or 18.2%, compared to the same period last year, primarily due to increased expenses related to acquisitions.

#### Revenue

The following table sets forth the change in revenue for the nine months ended September 30, 2022 and 2021.

*(Dollars in thousands)*

|  | Products |  | Services |  | Total |  |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue — nine months 2021 | $311,170 |  | $153,599 |  | $464,769 |  |
| Change in revenue: |  |  |  |  |  |  |
| Volume | 25,282 | 8.1% | 4,338 | 2.8% | 29,620 | 6.4% |
| Divestitures | (22,965) | (7.4)% | (48,707) | (31.7)% | (71,672) | (15.4)% |
| Price/Mix | 113 | —% | — | —% | 113 | —% |
| Foreign currency translation | (12,938) | (4.2)% | (4,593) | (3.0)% | (17,531) | (3.8)% |
| Net change | (10,508) | (3.4)% | (48,962) | (31.9)% | (59,470) | (12.8)% |
| Revenue — nine months 2022 | $300,662 |  | $104,637 |  | $405,299 |  |

Total consolidated revenue for the nine months ended September 30, 2022, decreased $59.5 million, or 12.8%, compared to the same period last year, driven by divestitures of non-core businesses and the negative impacts of foreign exchange, partly offset by higher sales volumes. Revenue from divested businesses for the nine months ended September 30, 2021 was $71.7 million, foreign exchange negatively impacted revenue in the nine months ended September 30, 2022 by $17.5 million, and higher sales volumes resulted in a $29.6 million increase in revenue.

#### Gross profit and gross profit margins

The following table sets forth gross profit and gross profit margins for the nine months ended September 30, 2022 and 2021.

*(Dollars in thousands)*

|  | Nine Months Ended September 30, 2022 Gross Profit | Gross Profit Margin | 2021 Gross Profit | Gross Profit Margin | Change in Gross Profit $% |  | Change in Gross Profit Margin Percentage Points% |  |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Products | $118,817 | 39.5% | $130,919 | 42.1% | $(12,102) | (9.2)% | (2.6) | (6.2)% |
| Services | 40,786 | 39.0% | 66,641 | 43.4% | (25,855) | (38.8)% | (4.4) | (10.1)% |
| Total | $159,603 | 39.4% | $197,560 | 42.5% | $(37,957) | (19.2)% | (3.1) | (7.3)% |

43

Gross profit for the nine months ended September 30, 2022, decreased $38.0 million, or 19.2%, to $159.6 million, compared to $197.6 million for the nine months ended September 30, 2021. Gross profit margin for the nine months ended September 30, 2022 and September 30, 2021 were 39.4% and 42.5%, respectively. The decrease in products and services gross profit and gross profit margin is primarily a result of divestitures of $33.5 million, cost inflation, supply chain pressures, and higher freight costs.

#### Operating expenses

The following table sets forth the components of consolidated operating expenses for the nine months ended September 30, 2022 and 2021.

*(Dollars in thousands)*

|  | Nine Months Ended September 30, 2022 Amount | % Revenue | 2021 Amount | % Revenue | Change $% |  |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Selling, general and administrative expenses | $185,398 | 45.7% | $176,800 | 38.0% | $8,598 | 4.9% |
| Research and development expenses | 63,180 | 15.6% | 49,987 | 10.8% | 13,193 | 26.4% |
| Total operating expenses | $248,578 | 61.3% | $226,787 | 48.8% | $21,791 | 9.6% |

For the nine months ended September 30, 2022, SG&A expenses increased $8.6 million, or 4.9%, as compared to the same period last year, due to an increase in expenses for estimated costs from legal contingencies and other settlements of $19.2 million, expenses from acquired companies of $11.1 million, Volumetric contingent consideration of $12.0 million, and an increase in merger and acquisition expenses, partly offset by lower incentive compensation expense of $28.6 million and the absence of expenses from divested businesses of $12.0 million.

For the nine months ended September 30, 2022, R&D expenses increased $13.2 million, or 26.4%, as compared to the same period last year, due to expenses from acquisitions of $14.0 million and continued investments in growth initiatives, partly offset by the absence of expenses from divested businesses of $5.3 million.

### Three and nine months ended September 30, 2022 compared to three and nine months ended September 30, 2021

#### Loss from operations

The following table sets forth loss from operations for the three and nine months ended September 30, 2022 and 2021.

*(Dollars in thousands)*

|  | Three Months Ended September 30, 2022 | 2021 | Change $% |  | Nine Months Ended September 30, 2022 | 2021 | Change $% |  |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Loss from operations: | $(33,705) | $(17,208) | $(16,497) | 95.9% | $(88,975) | $(29,227) | $(59,748) | 204.4% |

For the three and nine months ended September 30, 2022 the increase in loss from operations, as compared to the same period in the prior year, was primarily driven by lower revenue, lower gross profit and higher operating expenses.

See “*Revenue,” “Gross profit and gross profit margins”* and “*Operating expenses”* above.

#### Interest and other income (expense), net

The following table sets forth the components of interest and other income (expense), net, for the three and nine months ended September 30, 2022 and 2021.

|  | Three Months Ended September 30, |  | Change Nine Months Ended September 30, |  | Change |
| --- | ---: | ---: | ---: | ---: | ---: |
| **(Dollars in thousands)** | **2022** | **2021** | **$2022** | **2021** | **$** |
| Foreign exchange (loss) gain, net | $(764) | $222 | $(986) $(4,193) | $2,279 | $(6,472) |
| Interest income (expense), net | 2,029 | 19 | 2,010 4,019 | (1,230) | 5,249 |
| Other income (expense), net | (4,767) | 315,618 | (320,385) (5,282) | 353,347 | (358,629) |
| Total interest and other income (expense), net | $(3,502) | $315,859 | $(319,361) $(5,456) | $354,396 | $(359,852) |

For the three and nine months ended September 30, 2022, foreign exchange (loss) gain, net, as compared to the same periods last year, reported a loss due to the strengthening of the U.S. Dollar relative to the Euro, British Pound and other currencies, which negatively impacted non-U.S. Dollar denominated assets held by U.S. Dollar functional currency entities and U.S. Dollar liabilities held by non-U.S. Dollar functional currency entities.

For the three and nine months ended September 30, 2022, the interest income (expense), net, increased as compared to the same period last year due to net interest earned on short-term investments using the cash proceeds from the 2021 divestitures and convertible debt issuance, partly offset by non-cash interest expense related to the convertible notes.

For the and nine months ended September 30, 2022, other income decreased, as compared to the same periods last year, due to: (1) the $2.8 million impairment loss related to the Company’s investment in Enhatch being recognized during the three months ended September 30, 2022; (2) the gain on sale of ODM of $38.5 million and the gain on sale of Simbionix of $273.8 million both being recognized during the three months ended September 30, 2021; and (3) the gain on sale of Cimatron of $38.5 million being recognized during the three months ended March 31, 2021.

#### Net income (loss)

The following tables set forth the primary components of net income (loss) for the three and nine months ended September 30, 2022 and 2021.

*(Dollars in thousands, except per share amounts)*

|  | Three Months Ended September 30, 2022 | 2021 | Change |
| --- | ---: | ---: | ---: |
| Loss from operations | $(33,705) | $(17,208) | $(16,497) |
| Other non-operating items: |  |  |  |
| Interest and other income (expense), net | (3,502) | 315,859 | (319,361) |
| (Provision) benefit for income taxes | (338) | (5,995) | 5,657 |
| Net (loss) income | (37,545) | 292,656 | (330,201) |
| Less: net (loss) attributable to redeemable non-controlling interest | (147) | — | (147) |
| Net (loss) income attributable to 3D Systems Corporation | $(37,398) | $292,656 | $(330,054) |
| Weighted average shares - basic and diluted | 127,991 | 122,663 | 5,328 |
| Weighted average shares - diluted | 127,991 | 125,289 | 2,702 |
| Net (loss) income per share - basic and diluted | $(0.30) | $2.39 | $(2.69) |
| Net (loss) income per share - diluted | $(0.30) | $2.34 | $(2.64) |

Net loss attributable to 3D Systems for the three months ended September 30, 2022, was $37.4 million, as compared to net income of $292.7 million for the three months ended September 30, 2021 due to the previously discussed changes in revenue, gross profit, operating expenses, and total interest and other income (expense), net.

*(Dollars in thousands, except per share amounts)*

|  | Nine Months Ended September 30, 2022 | 2021 | Change |
| --- | ---: | ---: | ---: |
| Loss from operations | $(88,975) | $(29,227) | $(59,748) |
| Other non-operating items: |  |  |  |
| Interest and other income (expense), net | (5,456) | 354,396 | (359,852) |
| (Provision) benefit for income taxes | (2,911) | 3,083 | (5,994) |
| Net (loss) income | (97,342) | 328,252 | (425,594) |
| Less: net (loss) attributable to redeemable non-controlling interest | (184) | — | (184) |
| Net (loss) income attributable to 3D Systems Corporation | $(97,158) | $328,252 | $(425,410) |
| Weighted average shares - basic | 127,478 | 122,178 | 5,300 |
| Weighted average shares - diluted | 127,478 | 124,839 | 2,639 |
| Net (loss) income per share - basic | $(0.77) | $2.69 | $(3.46) |
| Net (loss) income per share - diluted | $(0.77) | $2.63 | $(3.40) |

Net loss attributable to 3D Systems for the nine months ended September 30, 2022, was $97.2 million, as compared to net income of $328.3 million for the comparable period in 2021 due to the previously discussed changes in revenue, gross profit, operating expense, interest and other income (expense), net.

### Liquidity and Capital Resources

### Cash Flow

The Company currently funds its operations, including working capital and capital expenditures, and acquisitions through cash, cash equivalents and short-term investments and financing activities as necessary. We expect that cash, cash equivalents and short-term investments, and other sources of liquidity, such as issuing equity or debt securities, subject to market conditions, will be available and sufficient to meet all foreseeable cash requirements. The following is a summary of the changes in the Company’s cash flows followed by a brief discussion of these changes:

|  | Nine Months Ended September 30, 2022 | 2021 | Dollar Change |
| --- | ---: | ---: | ---: |
| Cash flow (used in)/provided by operating activities | $(52,449) | $62,652 | $(115,101) |
| Cash flow (used in)/provided by investing activities(a) | $(374,116) | $399,641 | $(773,757) |
| Cash flow (used in) financing activities | $(12,981) | $(36,202) | $23,221 |

(a) - Includes investing cash of $272.4 million, net, into short-term investments in 2022

#### Cash flow (used in)/provided by operating activities

Cash used by operating activities for the nine months ended September 30, 2022 was $52.4 million, while cash provided by operating activities for the nine months ended September 30, 2021 was $62.7 million. The decrease is due to the higher net losses in the nine months ended September 30, 2022 compared to the same period in 2021 and unfavorable changes in working capital of $22.1 million. Inventory balances increased throughout the first nine months of 2022 to manage supply chain challenges and as a result of the purchase of $23.9 million of inventory from a contract manufacturer in connection with our decision to terminate the manufacturing services arrangement.

#### Cash flow (used in)/provided by investing activities

For the nine months ended September 30, 2022, cash flow used in investing activities was $374.1 million, compared to $399.6 million cash provided by investing activities for the nine months ended September 30, 2021. The primary cash outflows in 2022 related to net investments of $272.4 million of excess cash in short-term investments, the cash used for acquisitions of $84.7 million, and capital expenditures of $17.1 million. The primary inflows of cash of $427.7 million related to proceeds for the nine months ended September 30, 2021 was due to the sale of Cimatron, ODM, and Simbionix, partly offset by capital expenditures of $14.8 million and the acquisitions of Allevi and Additive for $10.9 million.

#### Cash flow (used in)/provided by financing activities

Cash used in financing activities was $13.0 million for the nine months ended September 30, 2022, and $36.2 million for the nine months ended September 30, 2021. The primary outflow of cash for the nine months ended September 30, 2022 was due to taxes paid related to the net-share settlement of equity awards of $10.2 million and the payment for the acquisition of a non-controlling interest of $2.3 million. The primary outflow of cash for the nine months ended September 30, 2021 related to the repayment of the remaining balance of the outstanding 5-year $100.0 million secured term loan facility of $21.4 million, the taxes paid related to net-share settlement of equity awards of $10.4 million and the payment for the acquisition of a non-controlling interest of $4.0 million.

### Cash and Cash Equivalents and Short-Term Investments

At September 30, 2022, we had cash, cash equivalents and short-term investments on hand of $609.4 million, compared to $789.7 million at December 31, 2021. The decrease is primarily due to payments related to acquisitions of $84.7 million, net cash used in operations of $52.4 million, capital expenditures of $17.1 million, and payments related to the net-share settlement of equity awards of $10.2 million

Cash held outside the U.S. at September 30, 2022 was $80.0 million, or 23.5% of total cash and cash equivalents, compared to $62.5 million, or 20.6% of total cash and cash equivalents, at December 31, 2021. As our previously unremitted earnings have been subjected to U.S. federal income tax, we expect any repatriation of these earnings to the U.S. would not incur significant federal and state taxes. However, these dividends are subject to foreign withholding taxes that are estimated to result in the Company incurring tax costs in excess of the cost to obtain cash through other means. Cash equivalents are primarily comprised of funds held in money market instruments and are reported at their current carrying value, which approximates fair value due to the short-term nature of these instruments. Short-term investments primarily consist of investment grade bonds, certificates of deposit, commercial paper and short maturity bond funds all with maturities of generally less than twelve months. We strive to minimize our credit risk by investing primarily in investment grade, liquid instruments and limiting exposure to any one issuer depending upon credit quality.

### Material Cash Requirements

The Company's material cash requirements consist of the following contractual and other obligations:

#### Indebtedness

At September 30, 2022, we had $460.0 million of outstanding 0% convertible notes which mature in November of 2026 (the “Notes”). Management may consider pursuing additional long-term financing, market conditions permitting, when it is appropriate in light of cash requirements for operations or other strategic opportunities, which could result in higher financing costs.

#### Purchase Commitments

We have purchase commitments for goods and services under legally enforceable agreements with defined terms as to quantity, price, and timing of delivery.

#### Leases

At September 30, 2022, the Company had operating and financing lease obligations of $50.2 million, primarily related to real estate and equipment leases, of which approximately $2.9 million in payments are expected over the remainder of 2022. Additionally, the Company has $33.5 million in lease obligations at September 30, 2022 for which the leases have not commenced as the facilities are under construction by the landlord. For more information on the Company's leases, refer to Note 5 to the Financial Statements.

#### Sources of Funding to Satisfy Material Cash Requirements

The Company believes that it has the financial resources needed to meet its cash requirements over the next twelve months. Cash requirements for periods beyond the next twelve months will depend, among other things, on the Company’s profitability and its ability to manage working capital requirements. The Company may also borrow from various sources as described above.

#### Other Contractual Commitments

#### Convertible Notes

We were in compliance with all covenants of the Notes as of September 30, 2022.

#### Other

We are committed to an initial investment of about $6.5 million related to our Saudi Arabia joint venture as described in Note 2 to the Financial Statements. Additional future investments in this relationship are contingent upon the achievement of certain milestones by the joint venture.

#### Indemnification

In the normal course of business we periodically enter into agreements to indemnify customers or suppliers against claims of intellectual property infringement made by third parties arising from the use of our products. Historically, costs related to these indemnification provisions have not been significant. We are unable to estimate the maximum potential impact of these indemnification provisions on our future results of operations.

To the extent permitted under Delaware law, we indemnify our directors and officers for certain events or occurrences while the director or officer is, or was, serving at our request in such capacity, subject to limited exceptions. The maximum potential amount of future payments we could be required to make under these indemnification obligations is unlimited; however, we have directors’ and officers’ insurance coverage that may enable us to recover future amounts paid, subject to a deductible and to the policy limits.

### Recent Accounting Pronouncements

Refer to Note 1 to the Financial Statements for further discussion.

### Critical Accounting Policies and Significant Estimates

Our condensed consolidated financial statements are prepared in accordance with GAAP. The preparation of these condensed consolidated financial statements requires us to make certain estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, costs and expenses, and related disclosures. On an ongoing basis, we evaluate our estimates and assumptions. Our actual results may differ from these estimates under different assumptions or conditions.

As of the date of this report, there have been no changes to our critical accounting policies and estimates described in the 2021 Form 10-K that have had a material impact on our condensed consolidated financial statements and related notes other than the implementation of policies for Short-Term Investments and Redeemable Non-Controlling Interest as described in Note 1 to the Financial Statements.

### Forward-Looking Statements

Certain statements made in this Form 10-Q that are not statements of historical or current facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. In many cases, you can identify forward-looking statements by terms such as “believes,” “belief,” “expects,” “may,” “will,” “estimates,” “intends,” “anticipates,” or “plans” or the negative of these terms or other comparable terminology.

Forward-looking statements are based upon management’s beliefs, assumptions and current expectations concerning future events and trends, using information currently available, and are necessarily subject to uncertainties, many of which are outside our control. Although we believe that the expectations reflected in the forward-looking statements are reasonable, forward-looking statements are not, and should not be relied upon as a guarantee of future performance or results, nor will they necessarily prove to be accurate indications of the times at or by which any such performance or results will be achieved. A number of important factors could cause actual results to differ materially from those expressed in or implied by the forward-looking statements. These factors include without limitation:

- impact of production, supply, contractual and other disruptions, including facility closures, furloughs and labor shortages or attrition as a result of vaccination requirements, due to the spread of the COVID-19 pandemic;
- impact on our business as a result of macroeconomic events, including the Russia-Ukraine war and other geopolitical risks, recession, supply chain disruptions and foreign exchange volatility;
- our ability to deliver products that meet changing technology and customer needs;
- our ability to identify strategic acquisitions, to integrate such acquisitions into our business without disruption and to realize the anticipated benefits of such acquisitions;
- impact of future write-off or write-downs of goodwill and intangible assets;
- the concentration of revenue and credit risk exposure from our largest customer;
- our ability to acquire and enforce intellectual property rights and defend such rights against third party claims;
- our ability to protect our intellectual property rights and confidential information, including our digital content, from third-party infringers or unauthorized copying, use or disclosure;
- failure of our information technology infrastructure or inability to protect against cyber-attack;
- our ability to predict quarterly sales and manage product inventory due to uneven sales cycle;
- our ability to generate net cash flow from operations;
- our ability to service our debt and ability to raise funds necessary to settle conversions of the Notes in cash, repay the Notes at maturity, or repurchase the Notes in the case of a fundamental change;
- our ability to remediate material weaknesses in our internal controls over financial reporting and maintain effective internal controls;
- fluctuations in our gross profit margins, operating income or loss and/or net income or loss;
- our ability to efficiently conduct business outside the U.S.;
- our dependence on our supply chain for components and sub-assemblies used in our 3D printers and other products and for raw materials used in our print materials;
- our ability to manage the costs and effects of litigation, investigations or similar matters involving us or our subsidiaries;
- product quality problems that result in decreased sales and operating margin, product returns, product liability, warranty or other claims;
- our ability to retain our key employees and to attract and retain new qualified employees, while controlling our labor costs;
- our ability to successfully develop and commercialize regenerative medicine products ourselves, or in conjunction with development partners;
- disruption in our management information systems for inventory management, distribution, and other key functions;
- compliance with U.S. and other anti-corruption laws, data privacy laws, trade controls, economic sanctions, and similar laws and regulations;
- our ability to maintain our status as a responsible contractor under federal rules and regulations;
- changes in, or interpretation of, tax rules and regulations; and
- the other factors discussed in the reports we file with or furnish to the SEC from time to time, including the risks and important factors set forth in additional detail in Item 1A. “Risk Factors” in the 2021 Form 10-K and our Form 10-Q for the quarter ended June 30, 2022.

Readers are cautioned not to place undue reliance on these forward-looking statements. The forward-looking statements included herein are made only as of the date of this Form 10-Q and we undertake no obligation to publicly update or revise any forward-looking statement made by us or on our behalf, whether as a result of new information, future developments, subsequent events or circumstances or otherwise, except as required by law. All subsequent written or oral forward-looking statements attributable to us or individuals acting on our behalf are expressly qualified in their entirety by the cautionary statements referenced above.

## Market risk

As filed, 331 characters.

For a discussion of market risks at December 31, 2021, refer to Item 7A. “Quantitative and Qualitative Disclosures about Market Risk” in our 2021 Form 10-K. During the first nine months of 2022, there were no material changes or developments that would materially alter the market risk assessment performed as of December 31, 2021.

## Controls and procedures

As filed, 8,305 characters.

### Evaluation of disclosure controls and procedures

As of September 30, 2022, we carried out an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) of the Exchange Act) pursuant to Rules 13a-15 and 15d-15 under the Exchange Act. These controls and procedures are designed to provide reasonable assurance that the information required to be disclosed in the reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the SEC’s rules and forms and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, in a manner to allow timely decisions regarding required disclosures. Based on this evaluation, management has concluded that our disclosure controls and procedures were not effective as of September 30, 2022 because of the material weaknesses in internal control over financial reporting discussed below.

Our management, including our Chief Executive Officer and Chief Financial Officer, concluded that material weaknesses in internal control over financial reporting existed at December 31, 2021. While the Company is in process of remediating the material weaknesses, they continued to exist as of September 30, 2022. These material weaknesses relate to a lack of certain controls, or improper execution of designed control procedures in the following areas:

- for certain non-standard contracts and non-standard contract terms;
- over the review of internally prepared reports and analyses utilized in the financial closing process; and
- for the calculation of the Company’s provision for income taxes, including for material non-routine transactions.

The combination of control deficiencies that resulted in these material weaknesses were partially related to employee training, resulting in a gap in knowledge or skills needed to properly execute the designed controls or perform an effective review over certain manual controls related to the financial statement close process. In addition, certain control deficiencies related to the timely review of transactions that were infrequent in nature.

### Remediation Plan

The first two material weaknesses described above (the “2020 Material Weaknesses”) were initially identified at December 31, 2020 and continued to exist at December 31, 2021. However, as a result of the remediation plan we commenced in January 2021, the volume of control deficiencies that aggregated into the 2020 Material Weaknesses at December 31, 2021 were significantly reduced compared to 2020. The remediation plan we began in January 2021 is designed to improve our internal control over financial reporting and remediate the related control deficiencies that led to these material weaknesses. To fully remediate the 2020 Material Weaknesses, we are executing the following additional remediation actions, which commenced in the first quarter of 2022:

1\. Hire additional staff with appropriate accounting, finance, operational and technology knowledge and experience in the design and execution of controls. Specifically, we hired several additional individuals with relevant accounting experience in the second quarter of 2022. We also retained additional interim personnel and consultants to assist with the execution of controls in the first, second, and third quarters of 2022.

2\. Re-design ineffective controls or processes. We retained an outside firm with expertise in the design and

execution of internal controls over financial reporting to examine our control designs and perform a root cause analysis as to why certain controls have not been and continue to not be properly executed.

3\. Implement or enhance software to improve our financial close and reporting process. We are in process of enhancing our account reconciliation software and implementing software to facilitate the recording of journal entries, transaction matching and task management. We are also implementing revenue accounting software and integrating a significant non-U.S. subsidiary onto our enterprise resource planning system.

4\. Established a formal controls governance committee in the first quarter of 2022 to manage and enhance the oversight and execution of internal controls. The controls governance committee consists of members of senior leadership, which meets monthly or more frequently as needed.

In addition to the remediation plan for the 2020 Material Weaknesses discussed above, we have supplemented our remediation plan to address the tax material weakness identified at December 31, 2021, and plan to implement a number of remediation actions in 2022 to address this tax material weakness, including:

1\. Retained a consulting firm to facilitate the implementation of a tax accounting and reporting solution for our tax provision process.

2\. Redesigned controls related to the accounting for the income tax process.

3\. Engaged a third party to review our quarterly and annual tax accounting calculations.

4\. Hire additional experienced resources with backgrounds in income tax accounting. We are in process of recruiting additional experienced tax accounting personnel to assist with the design and execution of tax accounting controls.

The planned or in process remedial actions discussed above are in addition to the following remediation actions completed in 2021 and 2022 to address the 2020 Material Weaknesses:

1\. Hired additional accounting personnel some of whom possess public company accounting and financial reporting technical expertise.

2\. Enhanced the monthly close process to improve the timeliness of recording entries which permits more time to

review and analyze financial statement accounts and to execute control procedures.

3\. Trained new and existing accounting and finance personnel as well as key personnel in other functions such as, operations, sales, business development, human resources, legal and supply chain on the newly enhanced, developed and implemented policies and procedures.

4\. Trained relevant personnel as to the proper design and execution of control procedures and noted the importance of the ongoing execution and maintenance of control process and procedures.

5\. Modified existing software to capture non-standard terms and conditions related to certain customer contracts.

6\. Designed and tested a significant number of additional business process and information technology controls throughout 2021.

7\. Formally enhanced, developed, and implemented policies, procedures and processes relating to our accounting and financial reporting.

We are in process of remediating all material weaknesses and are striving to successfully implement enhanced control processes and have a sufficient period of operational effectiveness to evidence material weakness remediation in 2022. However, as we continue to evaluate, and work to improve our internal control over financial reporting, management may determine that additional measures to address control deficiencies or modifications to the remediation plan are necessary. Therefore, we cannot assure you when we will remediate such material weaknesses, nor can we be certain that additional actions will not be required or the incremental costs of any such additional actions. Moreover, we cannot assure you that additional material weaknesses will not arise in the future.

### Changes in Internal Control over Financial Reporting

We are in the process of implementing certain changes in our internal control over financial reporting to remediate the material weaknesses that existed at December 31, 2021, as described above. The implementation of the material aspects of our remediation plan are ongoing. Except as noted above with respect to the implementation of the remediation plan, there have been no additional changes in our internal control over financial reporting during the quarter ended September 30, 2022 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

## Risk factors

As filed, 269 characters.

There are no material changes to the risk factors previously disclosed in our 2021 Form 10-K in response to Item 1A to Part I of Form 10-K and in our Form 10-Q for the quarterly period ended June 30, 2022 in response to Item 1A to Part II of Form 10-Q other than below.

Filed Nov 9, 2022.
Source: SEC EDGAR, the filing index for accession 0000910638-22-000046. Last ingested by Listed: Nov 15, 2026, 00:01 ET. No prices; not investment advice.
